Each year, the American Cancer Society estimates the numbers of new cancer cases and deaths in the United States and compiles the most recent data on population-based cancer occurrence and outcomes using incidence data collected by central cancer registries and mortality data collected by the National Center for Health Statistics. In 2023, 1,958,310 new cancer cases and 609,820 cancer deaths are projected to occur in the United States. Cancer incidence increased for prostate cancer by 3% annually from 2014 through 2019 after two decades of decline, translating to an additional 99,000 new cases; otherwise, however, incidence trends were more favorable in men compared to women. For example, lung cancer in women decreased at one half the pace of men (1.1% vs. 2.6% annually) from 2015 through 2019, and breast and uterine corpus cancers continued to increase, as did liver cancer and melanoma, both of which stabilized in men aged 50 years and older and declined in younger men. However, a 65% drop in cervical cancer incidence during 2012 through 2019 among women in their early 20s, the first cohort to receive the human papillomavirus vaccine, foreshadows steep reductions in the burden of human papillomavirus-associated cancers, the majority of which occur in women. Despite the pandemic, and in contrast with other leading causes of death, the cancer death rate continued to decline from 2019 to 2020 (by 1.5%), contributing to a 33% overall reduction since 1991 and an estimated 3.8 million deaths averted. This progress increasingly reflects advances in treatment, which are particularly evident in the rapid declines in mortality (approximately 2% annually during 2016 through 2020) for leukemia, melanoma, and kidney cancer, despite stable/increasing incidence, and accelerated declines for lung cancer. In summary, although cancer mortality rates continue to decline, future progress may be attenuated by rising incidence for breast, prostate, and uterine corpus cancers, which also happen to have the largest racial disparities in mortality.

中文翻译：

---

癌症统计数据，2023 年

每年，美国癌症协会都会估计美国的新癌症病例数和死亡人数，并使用中央癌症登记处收集的发病率数据和国家中心收集的死亡率数据，汇编有关基于人群的癌症发生率和结果的最新数据健康统计。2023 年，美国预计将出现 1,958,310 例新癌症病例和 609,820 例癌症死亡病例。在经历了二十年的下降后，从 2014 年到 2019 年，前列腺癌的癌症发病率每年增加 3%，意味着新增 99,000 例新病例；然而，除此之外，与女性相比，男性的发病率趋势更为有利。例如，从 2015 年到 2019 年，女性肺癌的下降速度是男性的一半（每年 1.1% 对 2.6%），乳腺癌和子宫体癌继续增加，肝癌和黑色素瘤也是如此，这两种癌症在 50 岁及以上的男性中趋于稳定，而在年轻男性中有所下降。然而，从 2012 年到 2019 年，20 岁出头的女性（第一批接种人乳头瘤病毒疫苗的女性）的宫颈癌发病率下降了 65%，这预示着人乳头瘤病毒相关癌症的负担急剧下降，其中大部分发生在女性。尽管发生了大流行，但与其他主要死亡原因相比，癌症死亡率从 2019 年到 2020 年继续下降（下降 1.5%），自 1991 年以来总体下降了 33%，估计避免了 380 万人死亡。这一进展越来越多地反映了治疗的进步，这在白血病、黑色素瘤和肾癌的死亡率快速下降（2016 年至 2020 年期间每年约 2%）方面尤为明显，尽管发病率稳定/上升，肺癌的死亡率也在加速下降。总之，尽管癌症死亡率继续下降，但未来的进展可能会因乳腺癌、前列腺癌和子宫体癌的发病率上升而减弱，而这些癌症恰好在死亡率方面存在最大的种族差异。